Phase II study of E7070 in patients with metastatic melanoma

J. F. Smyth; S. Aamdal; A. Awada; C. Dittrich; F. Caponigro; P. Schöffski; M. Gore; T. Lesimple; N. Djurasinovic; B. Baron; M. Ravic; P. Fumoleau; C. J. A. Punt

doi:https://doi.org/10.1093/annonc/mdi016

Phase II study of E7070 in patients with metastatic melanoma

J. F. Smyth, S. Aamdal, A. Awada, C. Dittrich, F. Caponigro, P. Schöffski, M. Gore, T. Lesimple, N. Djurasinovic, B. Baron, M. Ravic, P. Fumoleau, C. J. A. Punt

Other Departments

Research output: Contribution to journal › Article › Academic › peer-review

51 Citations (Scopus)

Abstract

E7070 is a synthetic chloro-indolyl sulphonamide that is being developed as an anti cancer agent. In this phase II study, 28 patients with metastatic melanoma received 700 mg/m(2) of E7070 as a 60-min infusion repeated every 3 weeks. Although therapy was well tolerated, with one patient receiving 14 courses of treatment, there were only minor responses on independent radiological review. E7070 does not warrant further development as a single agent for the treatment of metastatic melanoma

Original language	English
Pages (from-to)	158-161
Journal	Annals of Oncology
Volume	16
Issue number	1
DOIs	https://doi.org/10.1093/annonc/mdi016
Publication status	Published - 2005

Access to Document

https://doi.org/10.1093/annonc/mdi016

Cite this

@article{e99b4edb3b9f4202bae284aa577fea06,

title = "Phase II study of E7070 in patients with metastatic melanoma",

abstract = "E7070 is a synthetic chloro-indolyl sulphonamide that is being developed as an anti cancer agent. In this phase II study, 28 patients with metastatic melanoma received 700 mg/m(2) of E7070 as a 60-min infusion repeated every 3 weeks. Although therapy was well tolerated, with one patient receiving 14 courses of treatment, there were only minor responses on independent radiological review. E7070 does not warrant further development as a single agent for the treatment of metastatic melanoma",

author = "Smyth, {J. F.} and S. Aamdal and A. Awada and C. Dittrich and F. Caponigro and P. Sch{\"o}ffski and M. Gore and T. Lesimple and N. Djurasinovic and B. Baron and M. Ravic and P. Fumoleau and Punt, {C. J. A.}",

year = "2005",

doi = "https://doi.org/10.1093/annonc/mdi016",

language = "English",

volume = "16",

pages = "158--161",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "1",

}

TY - JOUR

T1 - Phase II study of E7070 in patients with metastatic melanoma

AU - Smyth, J. F.

AU - Aamdal, S.

AU - Awada, A.

AU - Dittrich, C.

AU - Caponigro, F.

AU - Schöffski, P.

AU - Gore, M.

AU - Lesimple, T.

AU - Djurasinovic, N.

AU - Baron, B.

AU - Ravic, M.

AU - Fumoleau, P.

AU - Punt, C. J. A.

PY - 2005

Y1 - 2005

N2 - E7070 is a synthetic chloro-indolyl sulphonamide that is being developed as an anti cancer agent. In this phase II study, 28 patients with metastatic melanoma received 700 mg/m(2) of E7070 as a 60-min infusion repeated every 3 weeks. Although therapy was well tolerated, with one patient receiving 14 courses of treatment, there were only minor responses on independent radiological review. E7070 does not warrant further development as a single agent for the treatment of metastatic melanoma

AB - E7070 is a synthetic chloro-indolyl sulphonamide that is being developed as an anti cancer agent. In this phase II study, 28 patients with metastatic melanoma received 700 mg/m(2) of E7070 as a 60-min infusion repeated every 3 weeks. Although therapy was well tolerated, with one patient receiving 14 courses of treatment, there were only minor responses on independent radiological review. E7070 does not warrant further development as a single agent for the treatment of metastatic melanoma

U2 - https://doi.org/10.1093/annonc/mdi016

DO - https://doi.org/10.1093/annonc/mdi016

M3 - Article

C2 - 15598954

SN - 0923-7534

VL - 16

SP - 158

EP - 161

JO - Annals of Oncology

JF - Annals of Oncology

IS - 1

ER -